Every material Form 8-K PETMED EXPRESS INC has filed with the SEC since September 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PetMed Express increased the share reserve under its 2024 Inducement Incentive Plan by 500,000 shares, bringing the total to 850,000, effective September 27, 2026. The increase covers equity grants promised to Jeffrey Allen Willard, the new Chief Executive Officer, whose start date is September 28, 2026, so the change adds potential dilution for shareholders.
Share reserve under the Inducement Incentive Plan rises by 500,000 shares to 850,000 total.
The increase matches 250,000 restricted stock shares plus 250,000 performance share units promised to CEO Jeffrey Allen Willard.
Willard's start date is September 28, 2026; the plan was amended and restated as of September 27, 2026.
No other changes were made to the original plan, per the filing.
PetMed Express appointed Tamar Elkeles, Ph.D., as an independent director effective September 17, 2026, increasing the board from 4 to 5 members. The company said the appointment follows its recent CEO transition and is part of board refresh and governance efforts; the filing reports no financial results or guidance.
Board appointment effective September 17, 2026; board size increased to 5 directors
Dr. Elkeles, age 57, will serve until the 2027 annual meeting; the board determined she is independent under Nasdaq listing standards
Appointed to the Compensation and Human Capital Committee and Corporate Governance and Nominating Committee; the press release describes her as Chair of the Compensation and Human Capital Committee
Press release dated September 21, 2026 is furnished as Exhibit 99.1 under Item 7.01
PetMed Express (PetMeds) appointed Jeff Willard as Chief Executive Officer, President and a director, effective September 28, 2026, succeeding Leslie C.G. Campbell, who has served as Interim CEO and President since August 2025. Campbell is also retiring as Board Chair and leaving the Board on the same date, and Justin Mennen will become Chair. The filing sets Willard's initial base salary at $550,000 and a three-year initial employment term, a significant change in the company's top leadership.
Jeff Willard, age 56, was CEO of Stewart-MacDonald from November 2024 to September 2026; the Board approved his appointment on August 27, 2026.
Initial base salary of $550,000, target annual bonus of 75% of base salary, and a $120,000 signing bonus.
Justin Mennen, currently Lead Independent Director, succeeds Leslie C.G. Campbell as Chair effective September 28, 2026.
Campbell will remain as a full-time Strategic Advisor for 60 days following Willard's arrival.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PETMED EXPRESS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →